Advertisement

Conformal External Beam Radiation Therapy

  • Arul Mahadevan
  • Patrick A. Kupelian
Chapter
Part of the Current Clinical Urology book series (CCU)

Abstract

External beam radiation therapy (RT) has been an essential component in the curative treatment of prostrate cancer for several decades. During the early clinical applications of cobalt beam teletherapy, the methods used to treat prostrate cancer relied on broad anatomic and physical principles that were applied in a general fashion to all patients with presumed localized disease. The target tissues (including the prostate, seminal vesicles, and pelvic lymph nodes) were not differentiated from the surrounding organs such as the bladder and the rectum, limiting the application of high radiation doses. The higher the radiation dose administered to a given volume of cancer, the more likely it is that the cancer will be permanently controlled—this is a basic tenet in radiation biology that has been clinically validated in several reports, both retrospective and prospective (1–7). In the last decade or so, the availability of high-energy megavoltage X-ray machines and the incorporation of cross-sectional imaging modalities and computerized treatment planning systems have been instrumental in the evolution of external radiation beam therapy as a safer and more effective option for men with localized prostate cancer. This chapter highlights the relevant clinical applied anatomy, the technical aspects of conformal external beam radiation therapy techniques, and the current disease control and quality of life outcome expectations.

Keywords

Prostate Cancer Seminal Vesicle Radiat Oncol Biol Phys Intensity Modulate Radiation Therapy Localize Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fiveash JB, Hanks G, Roach M, et al. 3D conformal radiation therapy (3DCRT) for high-grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 2000; 47: 335–342.PubMedCrossRefGoogle Scholar
  2. 2.
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097–1105.PubMedCrossRefGoogle Scholar
  3. 3.
    Kupelian PA, Mohan DS, Lyons J, et al. Higher than standard radiation doses ( -72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 567–574.PubMedCrossRefGoogle Scholar
  4. 4.
    Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491–500.PubMedCrossRefGoogle Scholar
  5. 5.
    Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000; 18: 2740–2746.PubMedGoogle Scholar
  6. 6.
    Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 1999; 5: 152–158.PubMedGoogle Scholar
  7. 7.
    Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional does irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32: 3–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Mizowaki T, Cohen GN, Fung AY, et al. Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasoundCT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 2002; 54: 1558–1564.PubMedCrossRefGoogle Scholar
  9. 9.
    Sannazzari GL, Ragona R, Ruo Redda MG, et al. CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. Br J Radiol 2002; 75: 603–607.PubMedGoogle Scholar
  10. 10.
    Krempien RC, Schubert K, Zierhut D, et al. Open low-field magnetic resonance imaging in radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 2002; 53: 1350–1360.PubMedCrossRefGoogle Scholar
  11. 11.
    Kitamura K, Shirato H, Seppenwoolde Y, et al. Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys 2002; 53: 1117–1123.PubMedCrossRefGoogle Scholar
  12. 12.
    Lattanzi J, McNeeley S, Donnelly S, et al. Ultrasound-based stereotactic guidance in prostate cancer— quantification of organ motion and set-up errors in external beam radiation therapy. Comput Aided Surg 2000; 5: 289–295.PubMedGoogle Scholar
  13. 13.
    Langen KM, Jones DT. Organ motion and its management. Int J Radiat Oncol Biol Phys 2001; 50: 265–278.PubMedCrossRefGoogle Scholar
  14. 14.
    Beard CJ, Kijewski P, Bussiere M, et al. Analysis of prostate and seminal vesicle motion: implications for treatment planning. Int J Radiat Oncol Biol Phys 1996; 34: 451–458.PubMedCrossRefGoogle Scholar
  15. 15.
    Crook JM, Raymond Y, Salhani D, et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995; 37: 35–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Melian E, Mageras GS, Fuks Z, et al. Variation in prostate position quantitation and implications for three-dimensional conformal treatment planning. Int J Radiat Oncol Biol Phys 1997; 38: 73–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Roeske JC, Forman JD, Mesina CF, et al. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 1995; 33: 1321–1329.PubMedCrossRefGoogle Scholar
  18. 18.
    Rudat V, Schraube P, Oetzel D, et al. Combined error of patient positioning variability and prostate motion uncertainty in 3D conformal radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 1027–1034.PubMedCrossRefGoogle Scholar
  19. 19.
    Vigneault E, Pouliot J, Laverdiere J, Roy J, Dorion M. Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. Int J Radiat Oncol Biol Phys 1997; 37: 205–212.PubMedCrossRefGoogle Scholar
  20. 20.
    Lattanzi J, McNeeley S, Hanlon A, et al. Ultrasound-based stereotactic guidance of precision conformal external beam radiation therapy in clinically localized prostate cancer. Urology 2000; 55: 73–78.PubMedCrossRefGoogle Scholar
  21. 21.
    Kuriyama K, Onishi H, Sano N, et al. A new irradiation unit constructed of self-moving gantry-CT and linac. Int J Radiat Oncol Biol Phys 2003; 55: 428–435.PubMedCrossRefGoogle Scholar
  22. 22.
    Hua C, Lovelock DM, Mageras GS, et al. Development of a semi-automatic alignment tool for accelerated localization of the prostate. Int J Radiat Oncol Biol Phys 2003; 55: 811–824.PubMedCrossRefGoogle Scholar
  23. 23.
    Ruchala KJ, Olivera GH, Kapatoes JM. Limited-data image registration for radiotherapy positioning and verification. Int J Radiat Oncol Biol Phys 2002; 54: 592–605.PubMedCrossRefGoogle Scholar
  24. 24.
    Mackie TR, Balog J, Ruchala K, et al. Tomotherapy. Semin Radiat Oncol 1999; 9: 108–117.CrossRefGoogle Scholar
  25. 25.
    Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1–2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043–1052.PubMedCrossRefGoogle Scholar
  26. 26.
    Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology 2000; 55: 382–386.PubMedCrossRefGoogle Scholar
  27. 27.
    Katcher J, Kupelian PA, Zippe C, Klein EA, Sohn JW. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 1997; 37: 871–876.PubMedCrossRefGoogle Scholar
  28. 28.
    Asbell SO, Krall JM, Pilepich MV, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77–06. Int J Radiat Oncol Biol Phys 1988; 15: 1307–1316.PubMedCrossRefGoogle Scholar
  29. 29.
    Roach M, DeSilvio M, Lawton C, et al. Neoadjuvant hormonal therapy (NHT) with whole-pelvic (WP) radiotherapy (RT) improves progression-free survival (PFS): RTOG (Radiation Therapy Oncology Group) 9413, a phase III randomized trial. J Urol 2002;10:1904–1911, Abs. #500164.Google Scholar
  30. 30.
    Rossi CJ Jr, Slater JD, Reyes-Molyneux N, et al. Particle beam radiation therapy in prostate cancer: is there an advantage? Semin Radiat Oncol 1998; 8: 115–123.PubMedCrossRefGoogle Scholar
  31. 31.
    Forman JD, Duclos M, Sharma R, et al. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio. Int J Radiat Oncol Biol Phys 1996; 35: 259–266.PubMedCrossRefGoogle Scholar
  32. 32.
    Laramore GE, Krall JM, Thomas FJ, et al. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. Am J Clin Oncol 1993; 16: 164–167.PubMedCrossRefGoogle Scholar
  33. 33.
    Russell KJ, Caplan RJ, Laramore GE. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int J Radiat Oncol Biol Phys 1994; 28: 47–54.PubMedCrossRefGoogle Scholar
  34. 34.
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035–1041.Google Scholar
  35. 35.
    Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate cancer. Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997; 79: 1370–1380.PubMedCrossRefGoogle Scholar
  36. 36.
    Zietman AL, Coen JJ, Dallow KC, et al. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995; 32: 287–292.PubMedCrossRefGoogle Scholar
  37. 37.
    Kupelian PA, Buchsbaum JC, Reddy CA. Radiation dose response in patients with favorable localized prostate cancer (stage T1–T2, biopsy Gleason 6, and pretreatment prostate-specific antigen 10). Int J Radiat Oncol Biol Phys 2001; 50: 621–625.PubMedCrossRefGoogle Scholar
  38. 38.
    Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299–1305.PubMedCrossRefGoogle Scholar
  39. 39.
    Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984; 10: 401–409.PubMedCrossRefGoogle Scholar
  40. 40.
    Perez CA, Michalski JM, Purdy JA, et al. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of nonrandomized comparison. Int J Radiat Oncol Biol Phys 2000; 47: 629–637.PubMedCrossRefGoogle Scholar
  41. 41.
    Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53: 1111–1116.PubMedCrossRefGoogle Scholar
  42. 42.
    Koper PC, Stroom JC, van Putten WL, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999; 43: 727–734.PubMedCrossRefGoogle Scholar
  43. 43.
    Pollack A, Zagars GK, Starkschall G, et al. Conventional vs conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34: 555–564.PubMedCrossRefGoogle Scholar
  44. 44.
    Zelefsky MJ, Fuks Z, Hunt M, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55: 241–249.PubMedCrossRefGoogle Scholar
  45. 45.
    Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 1999; 353: 267–272.PubMedCrossRefGoogle Scholar
  46. 46.
    Kupelian PA, Reddy CA, Klein EA. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 988–993.PubMedCrossRefGoogle Scholar
  47. 47.
    Schultheiss TE, Hanks GE, Hunt MA, et al. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 1995; 32: 643–649.PubMedCrossRefGoogle Scholar
  48. 48.
    Kupelian PA, Reddy CA, Carlson TP, et al. Dosevolume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: Absolute or relative rectal volume? Cancer 2002; 8: 62–66.CrossRefGoogle Scholar
  49. 49.
    Wilder RB, Chou RH, Ryu JK, et al. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results. Am J Clin Oncol 2000; 23: 330–333.PubMedCrossRefGoogle Scholar
  50. 50.
    Mantz CA, Song P, Farhangi E, et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 551–557.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Arul Mahadevan
  • Patrick A. Kupelian

There are no affiliations available

Personalised recommendations